Sergey Lunev

Sergey Lunev

Auto-generated profile, based on publicly available information

Sergey Lunev

Department of Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9700 AD Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SLSergey Lunev
Sergey Lunev
SBSabine Butzloff
Sabine Butzloff
ARAtilio R Romero
Atilio R Romero
MLMarleen Linzke
Marleen Linzke
FBFernando A Batista
Fernando A Batista
MGMatthew Groves
Matthew Groves
Malaria remains a major threat to human health, as strains resistant to current therapeutics are discovered. Efforts in finding new drug targets are hampered by the lack of sufficiently specific tools to provide target validation prior to initiating expensive drug discovery projects. Thus, new approaches that can rapidly enable drug target validation are of significant interest. In this manuscript we present the crystal structure of malate dehydrogenase from Plasmodium falciparum (PfMDH) at 2.4 Å resolution and structure-based mutagenic experiments interfering with the inter-oligomeric interactions of the enzyme. We report decreased thermal stability, significantly decreased specific activity and kinetic parameters of PfMDH mutants upon mutagenic disruption of either oligomeric interface. In contrast, stabilization of one of the interfaces resulted in increased thermal stability, increased substrate/cofactor affinity and hyperactivity of the enzyme towards malate production at sub-millimolar substrate concentrations. Furthermore, the presented data show that our designed PfMDH mutant could be used as specific inhibitor of the wild type PfMDH activity, as mutated PfMDH copies were shown to be able to self-incorporate into the native assembly upon introduction in vitro, yielding deactivated mutant:wild-type species. These data provide an insight into the role of oligomeric assembly in regulation of PfMDH activity and reveal that recombinant mutants could be used as probe tool for specific modification of the wild type PfMDH activity, thus offering the potential to validate its druggability in vivo without recourse to complex genetics or initial tool compounds. Such tool compounds often lack specificity between host or pathogen proteins (or are toxic in in vivo trials) and result in difficulties in assessing cause and effect—particularly in cases when the enzymes of interest possess close homologs within the human host. Furthermore, our oligomeric interference approach could be used in the future in order to assess druggability of other challenging human pathogen drug targets.

22 June 2016 in Acta Crystallographica Section F Structural Biology Communications
Verified
Journal Article
Open access
PDF file
SLSergey Lunev
Sergey Lunev
SBSoraya S. Bosch
Soraya S. Bosch
FBFernando de Assis Batista
Fernando de Assis Batista
CWCarsten Wrenger
Carsten Wrenger
MGMatthew Groves
Matthew Groves
Thede novopyrimidine-biosynthesis pathway ofPlasmodium falciparumis a promising target for antimalarial drug discovery. The parasite requires a supply of purines and pyrimidines for growth and proliferation and is unable to take up pyrimidines from the host. Direct (or indirect) inhibition ofde novopyrimidine biosynthesisviadihydroorotate dehydrogenase (PfDHODH), the fourth enzyme of the pathway, has already been shown to be lethal to the parasite. In the second step of the plasmodial pyrimidine-synthesis pathway, aspartate and carbamoyl phosphate are condensed toN-carbamoyl-L-aspartate and inorganic phosphate by aspartate transcarbamoylase (PfATC). In this paper, the 2.5 Å resolution crystal structure ofPfATC is reported. The space group of thePfATC crystals was determined to be monoclinicP21, with unit-cell parametersa= 87.0,b= 103.8,c= 87.1 Å, α = 90.0, β = 117.7, γ = 90.0°. The presentedPfATC model shares a high degree of homology with the catalytic domain ofEscherichia coliATC. There is as yet no evidence of the existence of a regulatory domain inPfATC. Similarly toE. coliATC,PfATC was modelled as a homotrimer in which each of the three active sites is formed at the oligomeric interface. Each active site comprises residues from two adjacent subunits in the trimer with a high degree of evolutional conservation. Here, the activity loss owing to mutagenesis of the key active-site residues is also described.

30 November 2016
Verified
Book Chapter
Open access
PDF file
SLSergey Lunev
Sergey Lunev
FBFernando A. Batista
Fernando A. Batista
SBSoraya S. Bosch
Soraya S. Bosch
CWCarsten Wrenger
Carsten Wrenger
MGMatthew Groves
Matthew Groves
Identification and Validation of Novel Drug Targets for the Treatment of Plasmodium falciparum Malaria: New Insights | InTechOpen, Published on: 2016-11-30. Authors: Sergey Lunev, Fernando A. Batista, Soraya S. Bosch, et

1 March 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SLSergey Lunev
Sergey Lunev
SBSoraya S. Bosch
Soraya S. Bosch
FBFernando A. Batista
Fernando A. Batista
CWChao Wang
Chao Wang
JLJingyao Li
Jingyao Li
MGMatthew Groves
Matthew Groves

2 June 2017 in Current Drug Targets
Verified
Journal Article
Closed access
KMKamila A. Meissner
Kamila A. Meissner
SLSergey Lunev
Sergey Lunev
YWYuan-Ze Wang
Yuan-Ze Wang
MLMarleen Linzke
Marleen Linzke
FBFernando de Assis Batista
Fernando de Assis Batista
MGMatthew Groves
Matthew Groves
The validation of drug targets in malaria and other human diseases remains a highly challenging process. In the vast majority of cases, highly specific small molecule tools to inhibit a proteins function in vivo are simply not available. Additionally, the use of genetic tools in the analysis of malarial pathways is challenging. These issues result in difficulties in specifically modulating a hypothetical drug target’s function in vivo. Thus, new approaches to identify a protein’s function in vivo are required to provide target validation in the drug discovery process. Oligomerisation is the assembly of two or more copies of a single protein into one object and this self-assembly is present in approximately one third of all protein structures. Thus, oligomerisation plays a central role in the generation of functional biomolecules. A key feature of oligomerisation is that the oligomeric interfaces between the individual parts of the final assembly are highly specific. However, these interface regions of essential plasmodial proteins have not yet been systematically explored or exploited as a method to dissect biochemical pathways in vivo. This mini review will describe initial efforts to exploit oligomerisation surfaces in drug target validation.

1 February 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
MGMatthew Groves
Matthew Groves
CSCarsten F.E. Schroer
Carsten F.E. Schroer
AMAdam J. Middleton
Adam J. Middleton
SLSergey Lunev
Sergey Lunev
NDNatasha Danda
Natasha Danda
CWChris Williams
Chris Williams
Pex4p is a peroxisomal E2 involved in ubiquitinating the conserved cysteine residue of the cycling receptor protein Pex5p. Previously, we demonstrated that Pex4p from the yeast Saccharomyces cerevisiae binds directly to the peroxisomal membrane protein Pex22p and that this interaction is vital for receptor ubiquitination. In addition, Pex22p binding allows Pex4p to specifically produce lysine 48 linked ubiquitin chains in vitro through an unknown mechanism. This activity is likely to play a role in targeting peroxisomal proteins for proteasomal degradation. Here we present the crystal structures of Pex4p alone and in complex with Pex22p from the yeast Hansenula polymorpha. Comparison of the two structures demonstrates significant differences to the active site of Pex4p upon Pex22p binding while molecular dynamics simulations suggest that Pex22p binding facilitates active site remodelling of Pex4p through an allosteric mechanism. Taken together, our data provide insights into how Pex22p binding allows Pex4p to build K48-linked Ub chains.